AbbVie has completed its acquisition of ImmunoGen Inc., which is now part of AbbVie, gaining its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The acquisition expands AbbVie’s commercial and clinical presence in the solid tumor space. ImmunoGen’s follow-on pipeline of  next-gen ADCs complements AbbVie’s ADC platform and existing programs.   ELAHERE is a fi...